ACRV | NVO | VRTX | REGN | SGEN | ARGX | |
---|---|---|---|---|---|---|
Company Name | Acrivon Therapeutics, Inc. Common Stock | Novo Nordisk A/S | Vertex Pharmaceuticals Incorporated | Regeneron Pharmaceuticals, Inc. | Seagen Inc. | argenx SE |
Sector | Healthcare | Healthcare | Healthcare | Healthcare | Healthcare | Healthcare |
Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Market Cap | $200.70M | $456.40B | $116.20B | $80.34B | $43.15B | $35.73B |
Employees | 0.06K | 71.88K | 5.40K | 14.17K | 3.26K | 1.15K |
CEO | Dr. Peter Blume-Jensen M.D., Ph.D. | Mr. Lars Fruergaard Jorgensen | Dr. Reshma Kewalramani FASN, M.D. | Dr. Leonard S. Schleifer M.D., Ph.D. | Mr. David R. Epstein B.Sc., M.B.A. | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. |